Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: HUNGARY - REVIEW
The Hungarian pharmaceutical market is one of the largest in the region. It is predicted to expand at a low CAGR over the next few years. Drug consumption is expected to rise as the economy recovers in 2011, although growth may be slow. Imports account for a large proportion of the market. The Hungarian pharmaceutical industry concentrates on generic production. Companies such as Gedeon Richter and Egis retain strong positions in the market, and are also prominent in the former Soviet Union. Demand is growing for expensive branded products, however.
The government has identified healthcare reform as a top priority and faces the challenge of financing the health sector with a health insurance fund budget that it considers to be inadequate. The public health insurance system accounts for around two thirds of total health expenditure, although the private sector is growing through increased co-payments and private insurance schemes. Health expenditure is expected to grow by a moderate CAGR in US dollar terms between 2011 and 2016, in line with economic growth. The economy contracted in 2009 but started to recover in 2010.
In January 2011, new rules on the opening and operation of pharmacies in Hungary came into force. Wholesalers, pharmaceutical companies and offshore investors are now prohibited from owning new pharmacies, and pharmacists will have to become majority stakeholders of existing pharmacies by January 2017. The rules governing pharmacy ownership have become increasingly more restrictive since the government decided to end the pharmacy liberalisation process in July 2010, by prohibiting the opening of new pharmacies, except for in towns which did not have one. The Pharmacy Liberalisation Act of 2007 saw the number of pharmacies increase rapidly, but as the number of redeemed prescriptions remained unchanged, price competition increased, leading to a number of pharmacies finding themselves on the verge of bankruptcy..
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
The Pharmaceutical Market: Hungary published by Espicom Business Intelligence in January 31, 2013. This report consists of 95 Pages and the price starts from US $ 1295.
The contents of this page may be different from the latest version. Please contact us for details.
